Cost-utility analysis of adding abiraterone acetate plus prednisone/prednisolone to long-term hormone therapy in newly diagnosed advanced prostate cancer in England: Lifetime decision model based on STAMPEDE trial data

Cost-utility analysis of adding abiraterone acetate plus prednisone/prednisolone to long-term hormone therapy in newly diagnosed advanced prostate cancer in England: Lifetime decision model based on STAMPEDE trial data

Show other versions (1)

Adding abiraterone acetate (AA) plus prednisolone (P) to standard of care (SOC) improves survival in newly diagnosed advanced prostate cancer (PC) patients starting hormone therapy. Our objective was to determine the value for money to the English National Health Service (NHS) of adding AAP to SOC....

Full description

Bibliographic Details
Main Authors: Caroline S. Clarke, Rachael M. Hunter, Andrea Gabrio, Christopher D. Brawley, Fiona C. Ingleby, David P. Dearnaley, David Matheson, Gerhardt Attard, Hannah L. Rush, Rob J. Jones, William Cross, Chris Parker, J. Martin Russell, Robin Millman, Silke Gillessen, Zafar Malik, Jason F. Lester, James Wylie, Noel W. Clarke, Mahesh K. B. Parmar, Matthew R. Sydes, Nicholas D. James
Format: Article
Language:English
Published: Public Library of Science (PLoS) 2022-01-01
Series:PLoS ONE
Online Access:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9162346/?tool=EBI

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9162346/?tool=EBI

Similar Items